Kiniksa Pharmaceuticals International, plc Kiniksa Pharmaceuticals International, plc

Kiniksa Pharmaceuticals International, plc

KNSA

Hisse Senetlerindeki Sıralama #2965
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Hisse Fiyatı
$80.60
Piyasa Değeri
$6.29B
Değişim (1 gün)
1.41%
Değişim (1 yıl)
106.72%
Ülke
GB
Ticaret Kiniksa Pharmaceuticals International, plc (KNSA)

Kategori

Healthcare
Kiniksa Pharmaceuticals International, plc (KNSA) için P/S oranı
October 2026 itibarıyla P/S oranı TTM: 7.32
Kiniksa Pharmaceuticals International, plc şirketinin en son mali raporları ve hisse fiyatına göre, mevcut P/S oranı (TTM) 7.32'dir. 2023 yılının sonunda şirketin P/S oranı 4.55 idi.
Kiniksa Pharmaceuticals International, plc için P/S oranı geçmişi 2016 - 2026 arası
Her yılın sonunda P/S oranı
Yıl P/S Oranı Değiştir
2026 (TTM) 7.32 119.03%
2024 3.34 -26.59%
2023 4.55 -3.68%
2022 4.72 -77.46%
2021 20.94 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
Benzer şirketler veya rakipler için P/S oranı